<p>Bicycle Therapeutics PLC 赞助的 ADR (NASDAQ:BCYC - 获取免费报告) 周四上涨了 9.8%，因为该公司公布的季度收益超出预期。该股最高交易价为 $8.73，最后交易价为 $8.98。在交易中，共成交 137,003 股，较平均交易量 309,305 股下降了 56%。该股此前收盘价为 $8.18。</p>
<p>该公司报告的每股收益 (EPS) 为 ($0.85)，超出市场共识预期的 ($1.05) 0.20 美元。Bicycle Therapeutics 的净利润率为 -1,257.00%，股本回报率为 -32.43%。</p>
<p>获取 <strong>Bicycle Therapeutics</strong> 的提醒：</p>
<h2>分析师评级上调与下调</h2>
<p>多位股票分析师最近对 BCYC 股票发表了评论。加拿大皇家银行在 8 月 11 日的研究报告中将 Bicycle Therapeutics 的目标价设定为 $27.00，并给予该股 &#34;跑赢大盘&#34; 的评级。JMP Securities 将 Bicycle Therapeutics 的目标价从 $22.00 下调至 $10.00，并在 8 月 12 日的报告中给予该股 &#34;市场跑赢&#34; 的评级。摩根士丹利在 8 月 12 日的报告中将 Bicycle Therapeutics 的目标价从 $17.00 下调至 $13.00，并给予该股 &#34;持平&#34; 的评级。Weiss Ratings 在 10 月 14 日的报告中重申了对 Bicycle Therapeutics 的 &#34;卖出 (d-)&#34; 评级。最后，Oppenheimer 在 8 月 11 日的研究报告中重申了 &#34;跑赢大盘&#34; 的评级，并将 Bicycle Therapeutics 的目标价下调至 $44.00（之前为 $48.00）。六位投资分析师对该股给予了买入评级，三位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该公司目前的平均评级为 &#34;适度买入&#34;，共识目标价为 $22.22。</p>
<p><strong>阅读我们对 Bicycle Therapeutics 的最新分析</strong></p>
<h2>内部人士买入与卖出</h2>
<p>在其他 Bicycle Therapeutics 的新闻中，首席执行官 Kevin Lee 于 10 月 3 日星期五出售了 3,231 股该股票。该股以平均价格 $8.41 出售，总价值为 $27,172.71。出售完成后，首席执行官持有该公司 475,310 股，价值 $3,997,357.10。这笔交易代表了他们持股比例的 0.68% 的减少。该出售在与 SEC 的法律文件中披露，文件可通过此链接获取。在过去的九十天里，内部人士共出售了价值 $71,738 的 8,527 股公司股票。公司内部人士持有公司股票的 22.90%。</p>
<h2>对 Bicycle Therapeutics 的对冲基金看法</h2>
<p>对冲基金最近买入和卖出了该公司的股票。Ausdal Financial Partners Inc. 在第二季度获得了 Bicycle Therapeutics 的新股份，价值约 $70,000。Sei Investments Co. 在第二季度购买了 Bicycle Therapeutics 的新股份，价值 $74,000。Virtus Investment Advisers LLC 在第二季度将其在 Bicycle Therapeutics 的股份增加了 32.6%。Virtus Investment Advisers LLC 目前持有该公司 10,821 股股票，价值 $75,000，此前在上一季度又增持了 2,659 股。Ameriprise Financial Inc. 在第二季度购买了 Bicycle Therapeutics 的新头寸，价值约 $86,000。最后，田纳西州财政部在第二季度购买了 Bicycle Therapeutics 的新头寸，价值约 $100,000。86.15% 的股票由机构投资者持有。</p>
<h2>Bicycle Therapeutics 股票上涨 9.7%</h2>
<p>该公司的市值为 $622.06 百万，市盈率为 -2.55，贝塔系数为 1.47。该公司的 50 日移动平均线为 $7.61，200 日移动平均线为 $7.86。</p>
<h2>Bicycle Therapeutics 公司简介</h2>
<p>(获取免费报告)</p>
<p>Bicycle Therapeutics plc 是一家临床阶段的生物制药公司，开发一类针对美国和英国现有治疗手段未能满足的疾病的药物。其产品管线包括 BT8009，一种正在进行 I/II/III 期临床试验的自行车毒素结合物 (BTC)，用于治疗高表达 nectin-4 的肿瘤；BT5528，一种正在进行 I/II 期临床试验的 BTC，用于治疗表达 Ephrin A 型受体 2 的肿瘤；BT7480，一种针对 Nectin-4 的自行车 TICA 分子，正在进行 I/II 期临床试验，并激活 CD137；以及 BT7455，一种针对 Ephrin A 型受体 2 和 CD137 的自行车 TICA 分子，正在进行临床前试验。</p>
<h2>另见</h2>
<ul>
<li>我们更看好的五只股票，胜过 Bicycle Therapeutics</li>
<li>如何在 7 个步骤中投资大麻股票</li>
<li>Carrier 股票在收益意外后显得被低估</li>
<li>除了喝咖啡，还有 3 种投资咖啡的方法</li>
<li>Alphabet 第三季度业绩大幅超预期，首次实现 $1000 亿季度</li>
<li>技术指标如何帮助你找到被超卖的股票</li>
<li>Rocket Lab 股票下跌 14%——是否存在买入机会？</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审核。如对该故事有任何问题或意见，请发送邮件至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 $1,000 在 Bicycle Therapeutics 吗？</h2>
<p>在考虑 Bicycle Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐，现在就买入，以便在更广泛的市场注意到之前……而 Bicycle Therapeutics 并不在名单上。</p>
<p>虽然 Bicycle Therapeutics 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得买入。</p>
<p>在这里查看这五只股票</p>

BCYC

<p>Bicycle Therapeutics（纳斯达克代码：BCYC）在报告季度收益好于预期后，股价上涨了 9.8%，每股收益为（$0.85），超出预期的（$1.05）。该股最高交易价达到$8.73，收盘价为$8.98。分析师的评级意见不一，普遍目标价为$22.22。首席执行官 Kevin Lee 最近出售了 3,231 股，略微减少了他的持股比例。该公司专注于开发针对未被充分满足的疾病的药物，市值为 6.2206 亿美元，并得到了显著的机构投资支持</p>

<p>Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC - Get Free Report) traded up 9.8% on Thursday after the company announced better than expected quarterly earnings. The company traded as high as $8.73 and last traded at $8.98. 137,003 shares traded hands during trading, a decline of 56% from the average session volume of 309,305 shares. The stock had previously closed at $8.18.</p>
<div class="lb-trans"><p>Bicycle Therapeutics PLC 赞助的 ADR (NASDAQ:BCYC - 获取免费报告) 周四上涨了 9.8%，因为该公司公布的季度收益超出预期。该股最高交易价为 $8.73，最后交易价为 $8.98。在交易中，共成交 137,003 股，较平均交易量 309,305 股下降了 56%。该股此前收盘价为 $8.18。</p>
</div><p>The company reported ($0.85) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.05) by $0.20. Bicycle Therapeutics had a negative net margin of 1,257.00% and a negative return on equity of 32.43%.</p>
<div class="lb-trans"><p>该公司报告的每股收益 (EPS) 为 ($0.85)，超出市场共识预期的 ($1.05) 0.20 美元。Bicycle Therapeutics 的净利润率为 -1,257.00%，股本回报率为 -32.43%。</p>
</div><p>Get <strong>Bicycle Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Bicycle Therapeutics</strong> 的提醒：</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级上调与下调</h2>
</div><p>A number of equities analysts recently commented on BCYC shares. Royal Bank Of Canada set a $27.00 price objective on shares of Bicycle Therapeutics and gave the stock an &#34;outperform&#34; rating in a research note on Monday, August 11th. JMP Securities cut their price target on shares of Bicycle Therapeutics from $22.00 to $10.00 and set a &#34;market outperform&#34; rating on the stock in a report on Tuesday, August 12th. Morgan Stanley cut their price target on shares of Bicycle Therapeutics from $17.00 to $13.00 and set an &#34;equal weight&#34; rating on the stock in a report on Tuesday, August 12th. Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of Bicycle Therapeutics in a report on Tuesday, October 14th. Finally, Oppenheimer restated an &#34;outperform&#34; rating and issued a $44.00 price target (down from $48.00) on shares of Bicycle Therapeutics in a research report on Monday, August 11th. Six investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $22.22.</p>
<div class="lb-trans"><p>多位股票分析师最近对 BCYC 股票发表了评论。加拿大皇家银行在 8 月 11 日的研究报告中将 Bicycle Therapeutics 的目标价设定为 $27.00，并给予该股 &#34;跑赢大盘&#34; 的评级。JMP Securities 将 Bicycle Therapeutics 的目标价从 $22.00 下调至 $10.00，并在 8 月 12 日的报告中给予该股 &#34;市场跑赢&#34; 的评级。摩根士丹利在 8 月 12 日的报告中将 Bicycle Therapeutics 的目标价从 $17.00 下调至 $13.00，并给予该股 &#34;持平&#34; 的评级。Weiss Ratings 在 10 月 14 日的报告中重申了对 Bicycle Therapeutics 的 &#34;卖出 (d-)&#34; 评级。最后，Oppenheimer 在 8 月 11 日的研究报告中重申了 &#34;跑赢大盘&#34; 的评级，并将 Bicycle Therapeutics 的目标价下调至 $44.00（之前为 $48.00）。六位投资分析师对该股给予了买入评级，三位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该公司目前的平均评级为 &#34;适度买入&#34;，共识目标价为 $22.22。</p>
</div><p><strong>Read Our Latest Analysis on Bicycle Therapeutics</strong></p>
<div class="lb-trans"><p><strong>阅读我们对 Bicycle Therapeutics 的最新分析</strong></p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部人士买入与卖出</h2>
</div><p>In other Bicycle Therapeutics news, CEO Kevin Lee sold 3,231 shares of the stock in a transaction on Friday, October 3rd. The shares were sold at an average price of $8.41, for a total value of $27,172.71. Following the completion of the sale, the chief executive officer owned 475,310 shares in the company, valued at $3,997,357.10. This trade represents a 0.68% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders have sold a total of 8,527 shares of company stock valued at $71,738 in the last ninety days. Company insiders own 22.90% of the company's stock.</p>
<div class="lb-trans"><p>在其他 Bicycle Therapeutics 的新闻中，首席执行官 Kevin Lee 于 10 月 3 日星期五出售了 3,231 股该股票。该股以平均价格 $8.41 出售，总价值为 $27,172.71。出售完成后，首席执行官持有该公司 475,310 股，价值 $3,997,357.10。这笔交易代表了他们持股比例的 0.68% 的减少。该出售在与 SEC 的法律文件中披露，文件可通过此链接获取。在过去的九十天里，内部人士共出售了价值 $71,738 的 8,527 股公司股票。公司内部人士持有公司股票的 22.90%。</p>
</div><h2>Hedge Funds Weigh In On Bicycle Therapeutics</h2>
<div class="lb-trans"><h2>对 Bicycle Therapeutics 的对冲基金看法</h2>
</div><p>Hedge funds have recently bought and sold shares of the company. Ausdal Financial Partners Inc. acquired a new stake in Bicycle Therapeutics during the 2nd quarter worth approximately $70,000. Sei Investments Co. bought a new stake in shares of Bicycle Therapeutics in the 2nd quarter worth $74,000. Virtus Investment Advisers LLC grew its stake in shares of Bicycle Therapeutics by 32.6% in the 2nd quarter. Virtus Investment Advisers LLC now owns 10,821 shares of the company's stock worth $75,000 after acquiring an additional 2,659 shares in the last quarter. Ameriprise Financial Inc. bought a new position in Bicycle Therapeutics during the second quarter valued at about $86,000. Finally, State of Tennessee Department of Treasury bought a new position in Bicycle Therapeutics during the second quarter valued at about $100,000. 86.15% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>对冲基金最近买入和卖出了该公司的股票。Ausdal Financial Partners Inc. 在第二季度获得了 Bicycle Therapeutics 的新股份，价值约 $70,000。Sei Investments Co. 在第二季度购买了 Bicycle Therapeutics 的新股份，价值 $74,000。Virtus Investment Advisers LLC 在第二季度将其在 Bicycle Therapeutics 的股份增加了 32.6%。Virtus Investment Advisers LLC 目前持有该公司 10,821 股股票，价值 $75,000，此前在上一季度又增持了 2,659 股。Ameriprise Financial Inc. 在第二季度购买了 Bicycle Therapeutics 的新头寸，价值约 $86,000。最后，田纳西州财政部在第二季度购买了 Bicycle Therapeutics 的新头寸，价值约 $100,000。86.15% 的股票由机构投资者持有。</p>
</div><h2>Bicycle Therapeutics Stock Up 9.7%</h2>
<div class="lb-trans"><h2>Bicycle Therapeutics 股票上涨 9.7%</h2>
</div><p>The company has a market cap of $622.06 million, a P/E ratio of -2.55 and a beta of 1.47. The company's 50-day moving average is $7.61 and its two-hundred day moving average is $7.86.</p>
<div class="lb-trans"><p>该公司的市值为 $622.06 百万，市盈率为 -2.55，贝塔系数为 1.47。该公司的 50 日移动平均线为 $7.61，200 日移动平均线为 $7.86。</p>
</div><h2>Bicycle Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Bicycle Therapeutics 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.</p>
<div class="lb-trans"><p>Bicycle Therapeutics plc 是一家临床阶段的生物制药公司，开发一类针对美国和英国现有治疗手段未能满足的疾病的药物。其产品管线包括 BT8009，一种正在进行 I/II/III 期临床试验的自行车毒素结合物 (BTC)，用于治疗高表达 nectin-4 的肿瘤；BT5528，一种正在进行 I/II 期临床试验的 BTC，用于治疗表达 Ephrin A 型受体 2 的肿瘤；BT7480，一种针对 Nectin-4 的自行车 TICA 分子，正在进行 I/II 期临床试验，并激活 CD137；以及 BT7455，一种针对 Ephrin A 型受体 2 和 CD137 的自行车 TICA 分子，正在进行临床前试验。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Bicycle Therapeutics</li>
<li>How to invest in marijuana stocks in 7 steps</li>
<li>Carrier Stock Looks Undervalued After Earnings Surprise</li>
<li>3 Ways To Invest In Coffee, Other Than Drinking It</li>
<li>Alphabet Crushes Q3 Earnings, Reports First $100 Billion Quarter</li>
<li>How Technical Indicators Can Help You Find Oversold Stocks</li>
<li>Rocket Lab Stock Dips 14%—Buying Opportunity Ahead?</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过 Bicycle Therapeutics</li>
<li>如何在 7 个步骤中投资大麻股票</li>
<li>Carrier 股票在收益意外后显得被低估</li>
<li>除了喝咖啡，还有 3 种投资咖啡的方法</li>
<li>Alphabet 第三季度业绩大幅超预期，首次实现 $1000 亿季度</li>
<li>技术指标如何帮助你找到被超卖的股票</li>
<li>Rocket Lab 股票下跌 14%——是否存在买入机会？</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审核。如对该故事有任何问题或意见，请发送邮件至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Bicycle Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 $1,000 在 Bicycle Therapeutics 吗？</h2>
</div><p>Before you consider Bicycle Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Bicycle Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bicycle Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐，现在就买入，以便在更广泛的市场注意到之前……而 Bicycle Therapeutics 并不在名单上。</p>
</div><p>While Bicycle Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Bicycle Therapeutics 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得买入。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Bicycle Therapeutics（NASDAQ:BCYC）股价因业绩超预期上涨 9.8%